Company Overview - CorMedix Therapeutics is a diversified specialty pharmaceutical company focused on institutional settings of care, primarily offering injectable drugs used in hospitals and infusion centers [3] - The company has a strong financial profile with approximately $150 million in cash and close to zero net debt [3] Financial Projections - Revenue guidance for 2026 is projected to exceed $300 million, with EBITDA expected to be between $100 million and $125 million [3] - The company anticipates increasing its cash position throughout the year [3] Commercial Strategy - CorMedix has a scalable platform supported by a solid commercial team experienced across multiple therapeutic areas [4]

PresentationMarta Campos MartinezHead of Investor Relations Good afternoon, and thank you for joining us for this special conference call to discuss ROVI's acquisition of an injectable drug product manufacturing site in Phoenix, Arizona, which we announced yesterday. Joining me on the call today is Juan Lopez-Belmonte, ROVI's Chairman and Chief Executive Officer; and Javier Lopez-Belmonte, ROVI's Deputy Chairman and Chief Financial Officer who will discuss the strategic rationale for the acquisition as well ...